Please login to the form below

Not currently logged in
Email:
Password:

antibody drug conjugate

This page shows the latest antibody drug conjugate news and features for those working in and with pharma, biotech and healthcare.

Boehringer’s Corsico to be new GSK drug dev leader

Boehringer’s Corsico to be new GSK drug dev leader

headhunted from his role at Google-owned drug research division Calico a year ago. ... data. The company’s most advanced oncology assets are both in phase 2: a BCMA targeting antibody drug conjugate and a TCR T-cell immunotherapy being developed with

Latest news

  • AZ nabs US approval for new leukaemia drug Lumoxiti AZ nabs US approval for new leukaemia drug Lumoxiti

    AZ nabs US approval for new leukaemia drug Lumoxiti. Adds to firm's growing oncology franchise. ... regulator. The CD22-directed antibody-drug conjugate (ADC) – which seeks out an destroys cells bearing the CD22 transmembrane protein – is one of the

  • Daily Brief: GSK unveils R&D plan, Keytruda OK'd for lymphoma by NICE Daily Brief: GSK unveils R&D plan, Keytruda OK'd for lymphoma by NICE

    Expected launches in this period include two new dual therapy treatments for HIV, dolutegravir lamivudine and cabotegravir ripilvirine, and GSK’s most advanced new oncology treatment, 2857916 (BCMA antibody-drug conjugate), ... The UK list price of the

  • AbbVie slumps on trial results for would-be blockbuster Rova-T AbbVie slumps on trial results for would-be blockbuster Rova-T

    The fall-off is no surprise given that AbbVie has spent the last few months building up expectations for antibody-drug conjugate Rova-T (rovalpituzumab tesirine), pointing to its blockbuster sales ... Rova-T comprises an anti-DLL3 antibody linked to a

  • Seattle Genetics claims key US approval for Adcetris Seattle Genetics claims key US approval for Adcetris

    Adcetris (brentuximab vedotin), an antibody-drug conjugate, is the first new treatment for this type of lymphoma in more than 40 years, with the US regulator approving it for use alongside ... Crucially, Adcetris avoids the use of the chemotherapy drug

  • Pfizer’s leukaemia drug Mylotarg backed for use in EU Pfizer’s leukaemia drug Mylotarg backed for use in EU

    Pfizer’ s leukaemia drug Mylotarg backed for use in EU. The CHMP’s positive opinion could see the drug return to market after almost eight years. ... Mylotarg (gemtuzumab ozogamicin) was the first antibody-drug conjugate to reach the market nearly

More from news
Approximately 2 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    used to progress the clinical development of the company's immuno-oncology antibody therapeutics against the checkpoint targets CTLA-4 and PD-1. ... Also in January Immunomedics sold tiered royalty rights on global net sales of its antibody drug conjugate

  • Pharma deals continue to slide Pharma deals continue to slide

    Roche has licensed a monoclonal antibody in phase II to Dermira, a dermatology company. ... 250+. Immunogen (US). Jazz (IE, US). Collaboration and option. Phase I haematology-related antibody-drug conjugate plus 2 other projects.

  • Deal Watch February 2017 Deal Watch February 2017

    Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.

  • Deal Watch April 2016 Deal Watch April 2016

    Its lead compound, Rovalpituzumab tesirine (Rova-T), is a biomarker-specific antibody drug conjugate, in phase I/II targeting cancer stem cell protein DLL3. ... Phase I antibody drug conjugate targeting cancer stem cell protein DLL3.

  • Deal Watch January 2016 Deal Watch January 2016

    363. Complix/ Merck &Co. Collaboration. Drug discovery collaboration to develop Cell-Penetrating Alphabodies (CPABs) for the treatment of cancer. ... Abzena/(Partner nd). Licence . Novel site specific ThioBridge antibody drug conjugate (ADC) linker

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • Glythera strengthens its scientific advisory board and appoints CSO Glythera strengthens its scientific advisory board and appoints CSO

    Glythera has appointed new chief scientific officer Dr Robert Lutz to lead the advancement of the UK-based biotech's antibody drug conjugate portfolio.

  • Glythera appoints Dr Mike Owen Glythera appoints Dr Mike Owen

    Antibody drug conjugate development company, Glythera has appointed Dr Mike Owen as its non-executive director. ... At GSK, Owen was responsible for initiating and growing the group’s pre-clinical and clinical therapeutic antibody pipeline through

  • ADC Therapeutics expands team ADC Therapeutics expands team

    ADC Therapeutics expands team. Appointments preceed its first antibody drug conjugate trials. ... ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics